U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H14N4O5S
Molecular Weight 314.318
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ENMETAZOBACTAM

SMILES

[H][C@@]12CC(=O)N1[C@@H](C([O-])=O)[C@](C)(CN3C=C[N+](C)=N3)S2(=O)=O

InChI

InChIKey=HFZITXBUTWITPT-YWVKMMECSA-N
InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11+/m1/s1

HIDE SMILES / InChI

Molecular Formula C11H14N4O5S
Molecular Weight 314.318
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 11:48:59 GMT 2023
Edited
by admin
on Sat Dec 16 11:48:59 GMT 2023
Record UNII
80VUN7L00C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AAI-101
Preferred Name English
ENMETAZOBACTAM
INN  
Official Name English
OCID-5090
Code English
(2S,3S,5R)-3-METHYL-3-((3-METHYLTRIAZOL-3-IUM-1-YL)METHYL)-4,4,7-TRIOXO-4^6-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLATE
Systematic Name English
1H-1,2,3-TRIAZOLIUM, 3-(((2S,3S,5R)-2-CARBOXY-3-METHYL-4,4-DIOXIDO-7-OXO-4-THIA-1-AZABICYCLO(3.2.0)HEPT-3-YL)METHYL)-1-METHYL-, INNER SALT
Systematic Name English
enmetazobactam [INN]
Common Name English
Code System Code Type Description
NCI_THESAURUS
C171696
Created by admin on Sat Dec 16 11:48:59 GMT 2023 , Edited by admin on Sat Dec 16 11:48:59 GMT 2023
PRIMARY
PUBCHEM
23653540
Created by admin on Sat Dec 16 11:48:59 GMT 2023 , Edited by admin on Sat Dec 16 11:48:59 GMT 2023
PRIMARY
SMS_ID
300000010200
Created by admin on Sat Dec 16 11:48:59 GMT 2023 , Edited by admin on Sat Dec 16 11:48:59 GMT 2023
PRIMARY
FDA UNII
80VUN7L00C
Created by admin on Sat Dec 16 11:48:59 GMT 2023 , Edited by admin on Sat Dec 16 11:48:59 GMT 2023
PRIMARY
CAS
1001404-83-6
Created by admin on Sat Dec 16 11:48:59 GMT 2023 , Edited by admin on Sat Dec 16 11:48:59 GMT 2023
PRIMARY
INN
10913
Created by admin on Sat Dec 16 11:48:59 GMT 2023 , Edited by admin on Sat Dec 16 11:48:59 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
We evaluated the in vitro potency of cefepime combined with AAI101, a novel extended-spectrum .BETA.-lactamase inhibitor, against a population of clinical Escherichia coli and Klebsiella pneumoniae collected from USA hospitals. Of the 223 cefepime non-susceptible isolates, 95% were ceftazidime non-susceptible, 49% ertapenem non-susceptible, 57% piperacillin/tazobactam non-susceptible, 90% were multidrug-resistant (resistant to 3 drug classes), 22% produced carbapenemases, and 67% produced ESBLs. Addition of AAI101 restored the activity of cefepime such that the MIC50 was reduced from >64 mg/L for cefepime to 0.13 mg/L for cefepime/AAI101, supporting its continued development treatment for infections caused by these organisms.